Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA (AAVIL-1Ra)

A Phase I Study Evaluating the Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Osteoarthritis of the Knee

This study seeks to determine the safety of three different doses of sc-rAAV2.5IL-1Ra delivered by intra-articular injection into one knee joint of patients with moderate OA of the knee.

Study Overview

• Status: Completed
• Conditions: Osteoarthritis, Knee
• Intervention / Treatment: Drug: sc-rAAV2.5IL-1Ra

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

• Age 18-80 years
• Gender: both males and females
• Target disease: Moderate OA of the knee
• Persistent symptoms, despite standard NSAID
• Absence of clinically significant abnormal values for the following:
• Complete blood count
• Prothrombin Time, Activated partial thromboplastin time
• Blood chemistry (Glucose, Na, K, Cl, CO2, BUN, creatinine, Ca, PO4, magnesium, uric acid)
• Liver function tests (amylase, total bilirubin, alkaline phosphate, GGT, AST, ALT, total protein, albumin)
• Able and willing to return to the Mayo Clinic for follow-up visits, as required by this study
• Able undergo MRI of the knee
• Subjects should be able to give appropriate consent.
• Potential subjects should have failed a three-month trial of a minimum of two conservative therapies before being considered for this trial. These conservative therapies include: activity modification, weight loss, physical therapy, and anti-inflammatory or injection therapy.

Exclusion Criteria

• Pregnant, or currently breast-feeding
• Ongoing infectious disease including HIV, HTLV, hepatitis, syphilis or tuberculosis positive
• Individuals who have OA as part of another syndrome (e.g. Ehler's Danlos, Stickler syndrome, etc.)
• Systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis.
• Clinically significant cardiovascular, renal, hepatic, endocrine disease, diabetes, cancer, autoimmune diseases; a serious infection or major operation within 30 days of enrollment; a history of untreated psychiatric disease or recent history of alcoholism or drug addiction.
• Currently taking immunosuppressant medications
• Anticipated major surgery during the study period.
• Individuals involved in another interventional protocol, or have been treated under one within the last 3 months.
• Intra-articular therapy in the index knee within the previous 3 months.
• Surgery to the target knee within 6 months prior to screening.
• Surgery to other weight bearing joints if it will interfere with knee assessments
• Prior articular transplant procedures
• Orthopedic hardware or implantable devices in the index knee
• Prior reconstruction surgery to the target knee within 12 months
• X-ray findings of acute fractures
• Known severe loss of bone density, and/or severe bone or joint deformity in the target knee.
• Significant target knee infection or overlying skin disorder/infection within the previous 6 months prior to study enrollment
• Require cane or other assistive device for walking
• Symptomatic OA of the hips, spine or ankle if it would interfere with the evaluation of the target knee,
• History of documented nerve damage in the affected limb, or vascular insufficiency,
• Condition requiring use of systemic steroids,
• Coagulation disorder.
• Patients with unstable knees
• Temperature above 99.5o F.
• Identification as a member of a vulnerable population.
• BMI greater than 40.
• History of allergy to local anesthetics
• Currently taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within the 3 months prior to entry in the study.
• Any illness or condition which, in the investigators' judgement will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Low Dose Group; Subjects will receive a single intra-articular 2mL injection consisting of 10{11} viral genomes.	Drug: sc-rAAV2.5IL-1Ra; Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.; Other Names: AAVIL-1Ra; IL-1Ra
EXPERIMENTAL: Medium Dose Group; Subjects will receive a single intra-articular 2mL injection consisting of 10{12} viral genomes.	Drug: sc-rAAV2.5IL-1Ra; Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.; Other Names: AAVIL-1Ra; IL-1Ra
EXPERIMENTAL: High Dose Group; Subjects will receive a single intra-articular 2mL injection consisting of 10{13} viral genomes.	Drug: sc-rAAV2.5IL-1Ra; Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.; Other Names: AAVIL-1Ra; IL-1Ra

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects experiencing severe adverse events.	Assess the local and systemic safety of three different doses of sc-rAAV2.5IL-1Ra delivered by intra-articular injection into one knee joint of patients with moderate OA of the knee.	53 weeks

Collaborators and Investigators

• Sponsor: Mayo Clinic
• Investigators: Principal Investigator: Christopher H. Evans, Ph.D., Mayo Clinic

Publications and helpful links

General Publications

• 2022 AMSSM Rising With Research Presentations. Clin J Sport Med. 2022 Mar 1;32(2):168-176. doi: 10.1097/JSM.0000000000001014. No abstract available.
• 2021 AMSSM Oral Research Poster Presentations. Clin J Sport Med. 2021 Mar 1;31(2):185-221. doi: 10.1097/JSM.0000000000000914. No abstract available.
• Mehta S, He T, Bajpayee AG. Recent advances in targeted drug delivery for treatment of osteoarthritis. Curr Opin Rheumatol. 2021 Jan;33(1):94-109. doi: 10.1097/BOR.0000000000000761.

Helpful Links

• Mayo Clinic Clinical Trials

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 5, 2019
• Primary Completion (ACTUAL): March 17, 2022
• Study Completion (ACTUAL): March 17, 2022

Study Registration Dates

• First Submitted: May 3, 2016
• First Submitted That Met QC Criteria: May 31, 2016
• First Posted (ESTIMATE): June 6, 2016

Study Record Updates

• Last Update Posted (ACTUAL): April 15, 2022
• Last Update Submitted That Met QC Criteria: April 14, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Antirheumatic Agents; Interleukin 1 Receptor Antagonist Protein
• Other Study ID Numbers: 15-007542

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No